Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NORMOZIDE vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Normozide is a combination of prazosin and polythiazide. Prazosin blocks alpha-1 adrenergic receptors, causing vasodilation and reduced peripheral resistance. Polythiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Oral: 10 mg once daily. Maximum dose: 20 mg once daily.
250 mg orally twice daily
Terminal elimination half-life is 8-12 hours in patients with normal renal function; prolonged to 20-30 hours in renal impairment (Cr Cl <30 m L/min). Clinical context: Dosing interval adjustments are required in renal disease to avoid accumulation.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Prazosin is extensively metabolized in the liver via demethylation and conjugation. Polythiazide is not significantly metabolized and is excreted unchanged in urine.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal excretion accounts for approximately 70% of elimination (30% as unchanged drug, 40% as inactive metabolites). Biliary/fecal elimination constitutes about 25%, with the remainder undergoing metabolic clearance.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Approximately 85-90% bound to serum albumin and alpha-1 acid glycoprotein.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
0.5-0.8 L/kg, indicating moderate distribution into extravascular tissues. Clinically, this suggests loading doses may be needed for rapid effect.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral bioavailability is 40-60% due to first-pass metabolism. Intravenous bioavailability is 100%.
70-90% (oral); 100% (IV).
GFR ≥60 m L/min: No adjustment. GFR 30-59 m L/min: Reduce dose to 5 mg once daily. GFR 15-29 m L/min: 2.5 mg once daily. GFR <15 m L/min: Not recommended.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 5 mg once daily. Child-Pugh C: Contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not approved for pediatric use. Safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Initiate at 5 mg once daily; titrate cautiously due to increased sensitivity and renal impairment risk.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Orthostatic hypotension and syncope, especially with first dose,Sodium and fluid depletion,Electrolyte imbalances (hypokalemia, hyponatremia),Renal impairment,Hepatic impairment,Possible increased risk of adverse effects in patients on beta-blockers or digitalis
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Hypersensitivity to prazosin, polythiazide, or sulfonamides,Anuria,Hepatic coma or precoma,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil)
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid high-potassium foods (bananas, oranges, spinach, potatoes, avocados) and potassium-containing salt substitutes. Grapefruit may increase drug levels; avoid grapefruit juice.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
NORMOZIDE is contraindicated in pregnancy (Category D). First trimester: Risk of fetal malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second and third trimesters: Increased risk of fetal renal dysfunction, oligohydramnios, and neonatal complications such as hypotension, hyperkalemia, and skull hypoplasia.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
NORMOZIDE is excreted in breast milk. M/P ratio: approximately 0.8. Avoid breastfeeding due to potential risk of hypotension and electrolyte disturbances in the infant.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
NORMOZIDE is not recommended in pregnancy. If used inadvertently, dose adjustments are not indicated; immediate discontinuation advised. Plasma levels may decrease in pregnancy due to increased volume of distribution, but no safe dosage can be established.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Monitor serum potassium and renal function before and during therapy due to risk of hyperkalemia. Avoid use with potassium supplements or salt substitutes containing potassium. Adjust dose in elderly and patients with hepatic impairment. Caution in patients with severe renal impairment (Cr Cl <30 m L/min).
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take exactly as prescribed, usually once daily.,Avoid potassium-rich foods and salt substitutes.,Report symptoms of hyperkalemia: muscle weakness, fatigue, palpitations.,May cause dizziness; avoid driving until effect known.,Do not stop abruptly without consulting prescriber.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NORMOZIDE vs ALDOCLOR-250, answered by our medical review team.
NORMOZIDE is a Antihypertensive Combination that works by Normozide is a combination of prazosin and polythiazide. Prazosin blocks alpha-1 adrenergic receptors, causing vasodilation and reduced peripheral resistance. Polythiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium and water.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NORMOZIDE and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NORMOZIDE is: Oral: 10 mg once daily. Maximum dose: 20 mg once daily.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NORMOZIDE and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NORMOZIDE is classified as Category C. NORMOZIDE is contraindicated in pregnancy (Category D). First trimester: Risk of fetal malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Seco. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.